PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, solidifying its position as a leading player in the industry. With the support of prominent investors such as Eight Roads, FIL Capital, and F-Prime, PlasmaGen has successfully raised over ₹600 crore to date.
The latest funding round is a testament to the company’s growth potential and its commitment to delivering high-quality products and services. PlasmaGen operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. The company’s state-of-the-art facility is designed to meet international standards, ensuring the production of high-quality plasma-derived products.
PlasmaGen’s success can be attributed to its focus on innovation, quality, and customer satisfaction. The company has established itself as a reliable partner for pharmaceutical companies, hospitals, and research institutions, providing them with a wide range of plasma-derived products. With its strong foundation in research and development, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived therapies in India and globally.
The Indian biotechnology sector has witnessed significant growth in recent years, driven by government initiatives, increasing investments, and a growing demand for innovative products and services. The sector is expected to continue its upward trajectory, with the Indian biotechnology market projected to reach $150 billion by 2025. PlasmaGen, with its strong portfolio of products and services, is well-positioned to benefit from this growth.
The company’s plasma fractionation facility is a critical component in the production of life-saving therapies, including immunoglobulins, albumin, and clotting factors. These products are used to treat a range of diseases and disorders, including immune disorders, bleeding disorders, and infectious diseases. With its state-of-the-art facility, PlasmaGen is able to produce high-quality plasma-derived products that meet international standards.
The funding round led by ViNS Bioproducts is a significant endorsement of PlasmaGen’s business model and growth potential. ViNS Bioproducts is a leading player in the biotechnology sector, with a strong portfolio of products and services. The company’s investment in PlasmaGen is a strategic move, aimed at expanding its presence in the Indian biotechnology sector.
Eight Roads, FIL Capital, and F-Prime, the other investors in PlasmaGen, have a strong track record of investing in innovative companies with high growth potential. Their investment in PlasmaGen is a testament to the company’s potential and its commitment to delivering high-quality products and services.
In conclusion, PlasmaGen’s latest funding round is a significant development in the Indian biotechnology sector. With its strong portfolio of products and services, commitment to quality and innovation, and state-of-the-art plasma fractionation facility, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived therapies in India and globally. The company’s valuation crossing ₹1,500 crore is a testament to its growth potential and its position as a leading player in the industry.
As the Indian biotechnology sector continues to grow, companies like PlasmaGen are expected to play a critical role in delivering innovative products and services. With the support of prominent investors and a strong foundation in research and development, PlasmaGen is poised to achieve significant growth and success in the years to come.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
